Clinical Trialist
Dr. med. Niklas Gremke
Department for Gynecology and Obstetrics, University Hospital Marburg
Research Focus: breast cancer, therapy resistance, autophagy, tumor cell metabolism, precision oncology
Contact: Gremken@staff.uni-marburg.de
Gremke Lab
The number of targeted molecular therapeutics in breast cancer treatment is rapidly increasing; however, acquired resistance still limits therapeutic success. Dr. Niklas Gremke and his research group investigate, among other approaches using CRISPR screens, the mechanisms underlying resistance to PI3K and CDK4/6 inhibitors and strategies to overcome them. Their recent work demonstrates that resistant tumor cells develop a metabolic vulnerability due to mTOR-mediated suppression of autophagy. In particular, therapy-induced aspartate depletion proved to be a key driver of cell death, highlighting novel opportunities for metabolism-based treatment strategies.
View the publication here.
Find out more about the Gremke Lab here.
